Table 1 Summary of published cases in the English literature reported as of July 2012 of docetaxel-related interstitial pneumonitis

[4]

44 to 77

NSCLC

Y

Y (67 percentage points)

Docetaxel

60

N

N/A

N/A

[5]

69

Prostate

Y

N

Docetaxel

75

N

Y

Death

[6]

46

Breast

N

N

TAC

75

N

Y

Resolution

[6]

64

Breast

Y

N

Docetaxel

75

N

Y

Death

[6]

52

Breast

Y

Y

Docetaxel

100

N

Y

Resolution

[6]

48

Breast

N

N

FEC then docetaxel

100

N

Y

Resolution

[7]

57

Gastric

N

Y

Docetaxel/S-1

35

N

Y

Resolution

[8]

63

Breast

N

N

DH

100

Y

Y

Death

[9]

71

GE junction

N

Y

Docetaxel

75

N

Y

Resolution

[10]

65

Breast

Y

N

Docetaxel/bevacizumab

100

Y

Y

Resolution

[11]

72

Prostate

Y

N

Docetaxel

30

N

Y

Death

[12]

U

Breast

U

U

Docetaxel

U

N

Y

Resolution

[13]

44 to 75

NSCLC

Y

Y

Docetaxel/gemcitabine

30 to 40

N

Y

Two deaths/four resolutions

[14]

78

Prostate

Y

N

Docetaxel/thalidomide

30

Y

Y

Resolution

[15]

73

Prostate

Y

N

Docetaxel

75

Y

Y

Death

[15]

74

Breast

Y

Y

Docetaxel

75

N

N

Death

[15]

61

Breast

N

N

AC then docetaxel

75

Y

Y

Resolution

[15]

54

Breast

Y

Y

Docetaxel

60

N

Y

Resolution

[16]

44

NSCLC

Y

Y

Docetaxel

33

N

Y

Death

[16]

73

NSCLC

Y

Y

Docetaxel/gemcitabine

30

Y

Y

Death

[16]

70

NSCLC

Y

Y

Docetaxel/gemcitabine

30

Y

Y

Death

[16]

75

NSCLC

Y

Y

Docetaxel

60

N

Y

Death

[18]

41

Breast

Y

Y

ThCD

125

N

Y

Resolution

[18]

48

Breast

Y

Y

ThCD

125

N

Y

Resolution

[17]

73

NSCLC

Y

N

Docetaxel

100

Y

Y

Resolution

[17]

67

NSCLC

Y

N

Docetaxel

100

Y

Y

Improvement